No increase in privatisation offer, Singapore Paincare confirms

The scheme document, including the notice of the scheme meeting, will be dispatched in due course.

The key shareholders of Singapore Paincare Holdings do not intend to increase the scheme consideration of $0.16 each to take the company private, according to a bourse filing on June 10.

“Therefore, by Rule 20.2 of the Code, save where a competitive situation arises, the offeror will not be allowed to subsequently revise the scheme consideration,” Singapore Paincare said.

The scheme document containing full details of the scheme including the notice of the scheme meeting will be despatched in due course.

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia